CA2978627A1 - Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance - Google Patents

Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance Download PDF

Info

Publication number
CA2978627A1
CA2978627A1 CA2978627A CA2978627A CA2978627A1 CA 2978627 A1 CA2978627 A1 CA 2978627A1 CA 2978627 A CA2978627 A CA 2978627A CA 2978627 A CA2978627 A CA 2978627A CA 2978627 A1 CA2978627 A1 CA 2978627A1
Authority
CA
Canada
Prior art keywords
thiazol
phenyl
trifluoromethanesulfonamide
chloro
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2978627A
Other languages
English (en)
French (fr)
Inventor
Sebastian Bernales
Jeffrey Lindquist
Mausumee Guha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivation Technologies LLC
Original Assignee
Medivation Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Technologies LLC filed Critical Medivation Technologies LLC
Publication of CA2978627A1 publication Critical patent/CA2978627A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CA2978627A 2015-03-04 2016-03-03 Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance Abandoned CA2978627A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562128251P 2015-03-04 2015-03-04
US62/128,251 2015-03-04
PCT/US2016/020644 WO2016141159A1 (en) 2015-03-04 2016-03-03 Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance

Publications (1)

Publication Number Publication Date
CA2978627A1 true CA2978627A1 (en) 2016-09-09

Family

ID=55754401

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2978627A Abandoned CA2978627A1 (en) 2015-03-04 2016-03-03 Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance

Country Status (5)

Country Link
US (1) US10183015B2 (https=)
EP (1) EP3265088A1 (https=)
JP (1) JP2018507234A (https=)
CA (1) CA2978627A1 (https=)
WO (1) WO2016141159A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016105491A1 (en) 2014-12-23 2016-06-30 Fgh Biotech Compositions of fatostatin based heterocyclic compounds and uses thereof
JP2018507235A (ja) 2015-03-04 2018-03-15 メディベイション テクノロジーズ エルエルシー ステロール調節エレメント結合タンパク質（ｓｒｅｂｐ）阻害剤
KR102498741B1 (ko) 2016-04-29 2023-02-10 에프지에이치 바이오테크 인코포레이티드 질환 치료용 이-치환된 피라졸 화합물
JP7071981B2 (ja) 2016-09-07 2022-05-19 エフジーエイチ バイオテック，インコーポレーテッド 疾患の治療のための二置換ピラゾール化合物
AU2019212959A1 (en) * 2018-01-29 2020-09-17 Capulus Therapeutics, Llc SREBP inhibitors comprising a 6-membered central ring
EP3917513A4 (en) * 2019-01-28 2022-11-09 Capulus Therapeutics, LLC SREBP INHIBITORS WITH A THIOPHENE CENTER RING
WO2020191163A1 (en) * 2019-03-20 2020-09-24 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors
CN114945365A (zh) * 2019-11-13 2022-08-26 卡普勒斯疗法有限责任公司 包括噻吩中心环的srebp抑制剂
TW202128676A (zh) * 2019-11-13 2021-08-01 美商卡普勒斯療法有限責任公司 具有環醯胺的噻吩化合物及其用途
WO2021154735A1 (en) * 2020-01-27 2021-08-05 Capulus Therapeutics, Llc Srebp inhibitors comprising a thiophene central ring
EP4185584A1 (en) * 2020-07-24 2023-05-31 Capulus Therapeutics, LLC Srebp inhibitors comprising a thiophene central ring

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
NZ506507A (en) 1998-02-09 2003-08-29 Dimensional Pharm Inc Heteroaryl amidine, methylamidine or guanidine derivatives useful as urokinase inhibitors
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
DE60022386T2 (de) 1999-12-16 2006-06-22 Schering Corp. Substituierte imidazole als neuropeptide y y5 rezeptor antagonisten
TWI275589B (en) 2000-06-22 2007-03-11 Dow Agrosciences Llc 2-(3,5-disubstituted-4-pyridyl)-4-(thienyl, thiazolyl or arylphenyl)-1,3-oxazoline compounds
JP4847868B2 (ja) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
WO2006135648A2 (en) 2005-06-09 2006-12-21 Schering-Plough Ltd. Control of parasites in animals by n-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and n-[(phenylsulfanyl)phenyl]-1,1,1-trifluoromethanesulfonamide derivatives
AR058439A1 (es) 2005-07-26 2008-02-06 Portela & Ca Sa Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas.
JP5261176B2 (ja) 2005-08-16 2013-08-14 アイカジェン， インコーポレイテッド 電位作動型ナトリウムチャンネル阻害剤
US8229106B2 (en) 2007-01-22 2012-07-24 D.S.P. Group, Ltd. Apparatus and methods for enhancement of speech
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
EP2120580B1 (en) 2007-02-02 2017-12-27 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
PT2125797E (pt) 2007-03-16 2014-03-11 Actelion Pharmaceuticals Ltd Derivados aminopiridina como agonistas do receptor s1p1/edg1
AU2008340113B2 (en) 2007-12-21 2014-01-09 Merck Serono S.A. Triazole oxadiazoles derivatives
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
WO2011085269A1 (en) 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Raf kinase inhibitors
WO2012084678A1 (en) 2010-12-23 2012-06-28 Syngenta Participations Ag Novel imidazoles useful as plant fungicides
JP2014062047A (ja) 2011-01-21 2014-04-10 Taisho Pharmaceutical Co Ltd ピラゾール誘導体
GB201116017D0 (en) 2011-09-16 2011-10-26 Univ Surrey Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors
WO2013096630A1 (en) 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US20140364460A1 (en) 2012-01-18 2014-12-11 The Trustees Of Columbia University In The City Of New York USE OF FATOSTATIN FOR TREATING CANCER HAVING A p53 MUTATION
WO2014199164A1 (en) 2013-06-12 2014-12-18 Ampla Pharmaceuticals, Inc. Diaryl substituted heteroaromatic compounds
EP3013371A4 (en) * 2013-06-26 2017-04-26 Rett Syndrome Research Trust Rett syndrome and treatments therefore
SG10201806370QA (en) * 2013-08-28 2018-08-30 Medivation Tech Llc Heterocyclic compounds and methods of use
JP2018507235A (ja) 2015-03-04 2018-03-15 メディベイション テクノロジーズ エルエルシー ステロール調節エレメント結合タンパク質（ｓｒｅｂｐ）阻害剤

Also Published As

Publication number Publication date
EP3265088A1 (en) 2018-01-10
JP2018507234A (ja) 2018-03-15
US10183015B2 (en) 2019-01-22
WO2016141159A1 (en) 2016-09-09
US20180028518A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
CA2978627A1 (en) Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance
JP7037679B2 (ja) 新規の二環式ブロモドメイン阻害剤
EP3038622B1 (en) Heterocyclic compounds and methods of use
JP7288527B2 (ja) Ｐｒｃ２阻害剤
KR101345497B1 (ko) 설폰아미드 유도체
AU2012345557A1 (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
JP2018514524A (ja) ５−芳香族アルキニル基置換ベンズアミド系化合物並びにその製造方法、薬物組成物及び使用
CN101595105A (zh) 作为scd抑制剂的2-取代的5元杂环化合物
CA2922703A1 (en) Compositions and methods for the treatment of metabolic and body weight related disorders
MX2008015229A (es) Compuestos organicos.
CA2890699A1 (en) Combination therapy
WO2005056522A2 (en) Indole compounds
JP2018507235A (ja) ステロール調節エレメント結合タンパク質（ｓｒｅｂｐ）阻害剤
CN111526877B (zh) 用于ire1抑制的化合物和组合物
TW202039447A (zh) 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh) 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
JP2025529797A (ja) 複素環ｒｂｍ３９モジュレーター
EP3687538A1 (en) Methods of treating elevated plasma cholesterol
JP2025542413A (ja) プロテインチロシンキナーゼ阻害剤及びその医療上の使用
JP2022507958A (ja) 代謝障害の治療用のプロタンパク質転換酵素サブチリシン／ケキシン９型（ｐｃｓｋ９）阻害薬としての環状四量体化合物
JP2025138791A (ja) 慢性腎臓病の治療又は予防方法
CA3115960A1 (en) Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
EP3893892A1 (en) Organic compounds

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210903